STUTTGART, Germany I August 15, 2016 I The majority of tumor-associated antigens are intracellular-derived antigens, not druggable with most conventional antibody technologies. T-Cell Receptor (TCR)-based treatment modalities can bind to proteolytically processed peptides derived from a cytosolic or membrane-associated protein presented within the groove of a specific major histocompabitility complex (MHC). However, identification of suitable peptide targets and corresponding TCRs, establishment of tumor specificity and optimization of TCR affinity requires specialized expertise, technologies and assays leading to high entry barriers for new companies.
The number of TCR T-cell programs in clinical stage is low compared to that of CAR T-cell programs and interim results from clinical studies are limited. The most advanced program is that of Adaptimmune in collaboration with partner GlaxoSmithKline targeting the HLA-A*0201/0206 restricted antigen NY-ESO-1. Interim data demonstrated robust clinical responses in solid and hematologic tumors, including a 50% (6/12) response rate in synovial sarcoma, and a 91% (20/22) response rate in multiple myeloma. Cytokine release syndrome was observed in 8/53 (15%) of patients. Adaptimmune expects to initiate a pivotal study of NY-ESO-1T in synovial sarcoma by end of 2016 or early 2017.
Nearly all of the TCR T-cell therapy candidates currently in development are directed against well known targets. In contrast to CAR T-cell technologies, most of the TCR technologies were developed and/or matured in house and most of the TCR companies are European. TCR-like antibody binding capabilities incorporated into T-cells are an intriguing convergence of TCR- and CAR-technologies.
In a new report released by La Merie Publishing, the competitive landscape of TCR T-Cell stakeholders, technologies, pipelines, financing and deals is described and analyzed.
This report „TCR & CAR Engineered T-Cell and NK Cell Therapeutics 2016: Convergence of technologies opens business opportunities beyond CD19 CARTs“ describes and analyzes the status of the adoptive cell therapy industry as of August 2016. The report covers autologous and allogeneic engineered chimeric antigen receptor (CAR) and T-cell receptor (TCR) T-cell therapy candidates as well as natural killer (NK) cell and CAR engineered NK cells in research and development by biopharmaceutical companies. Cytotoxic lymphocytes (CTLs), donor lymphocyte infusions (TILs) and tumor infiltrating lymphocytes (TILs) complement the spectrum of the report.
About La Merie
La Merie Publishing is a Business Intelligence enterprise fully dedicated to provide high quality R&D information to the biopharmaceutical industry. La Merie offers individual consultancy services and publishes reports and periodicals. For more information visit www.lamerie.com and www.PipelineReview.com, the Biologics News Center and Online Store of La Merie Publishing.
SOURCE: La Merie Publishing
Post Views: 20
STUTTGART, Germany I August 15, 2016 I The majority of tumor-associated antigens are intracellular-derived antigens, not druggable with most conventional antibody technologies. T-Cell Receptor (TCR)-based treatment modalities can bind to proteolytically processed peptides derived from a cytosolic or membrane-associated protein presented within the groove of a specific major histocompabitility complex (MHC). However, identification of suitable peptide targets and corresponding TCRs, establishment of tumor specificity and optimization of TCR affinity requires specialized expertise, technologies and assays leading to high entry barriers for new companies.
The number of TCR T-cell programs in clinical stage is low compared to that of CAR T-cell programs and interim results from clinical studies are limited. The most advanced program is that of Adaptimmune in collaboration with partner GlaxoSmithKline targeting the HLA-A*0201/0206 restricted antigen NY-ESO-1. Interim data demonstrated robust clinical responses in solid and hematologic tumors, including a 50% (6/12) response rate in synovial sarcoma, and a 91% (20/22) response rate in multiple myeloma. Cytokine release syndrome was observed in 8/53 (15%) of patients. Adaptimmune expects to initiate a pivotal study of NY-ESO-1T in synovial sarcoma by end of 2016 or early 2017.
Nearly all of the TCR T-cell therapy candidates currently in development are directed against well known targets. In contrast to CAR T-cell technologies, most of the TCR technologies were developed and/or matured in house and most of the TCR companies are European. TCR-like antibody binding capabilities incorporated into T-cells are an intriguing convergence of TCR- and CAR-technologies.
In a new report released by La Merie Publishing, the competitive landscape of TCR T-Cell stakeholders, technologies, pipelines, financing and deals is described and analyzed.
This report „TCR & CAR Engineered T-Cell and NK Cell Therapeutics 2016: Convergence of technologies opens business opportunities beyond CD19 CARTs“ describes and analyzes the status of the adoptive cell therapy industry as of August 2016. The report covers autologous and allogeneic engineered chimeric antigen receptor (CAR) and T-cell receptor (TCR) T-cell therapy candidates as well as natural killer (NK) cell and CAR engineered NK cells in research and development by biopharmaceutical companies. Cytotoxic lymphocytes (CTLs), donor lymphocyte infusions (TILs) and tumor infiltrating lymphocytes (TILs) complement the spectrum of the report.
About La Merie
La Merie Publishing is a Business Intelligence enterprise fully dedicated to provide high quality R&D information to the biopharmaceutical industry. La Merie offers individual consultancy services and publishes reports and periodicals. For more information visit www.lamerie.com and www.PipelineReview.com, the Biologics News Center and Online Store of La Merie Publishing.
SOURCE: La Merie Publishing
Post Views: 20
